LinkedIn
LinkedIn
Instagram
Instagram

OUR FOCUS

EOLO Pharma focuses on developing drugs targeting the molecular and cellular basis of inflammation-related diseases (e.g. Type II diabetes, autoimmune, metabolic syndrome, hypertension, atherosclerosis, etc) creating disruptive therapies for the treatment and prevention of the leading causes of death worldwide.

EOLO Pharma holds global patents based on over 15 years of scientific data developed by the founders.  The Company has conducted preclinical trials with exceptional results. The Company was founded by a multidisciplinary team of leading scientists from the prestigious Institut Pasteur de Montevideo (the South American branch of Institut Pasteur Paris).

THE PROBLEM:

In the last decade low grade, chronic, sterile inflammation has been recognized as a key player in the pathogenesis of cardiovascular (atherosclerosis, coronary heart disease, stroke, hypertension), metabolic (obesity, Type II Diabetes and metabolic syndrome), neurodegenerative (ALS; Alzheimer) and immunological disorders (autoinflammatory and autoimmune diseases).

Diabetes affects around 8.3% of the U.S. population (USD 24 Million), 12% of world health expenditure, around USD 673 billion. .

In the last decade low grade, chronic, sterile inflammation has been recognized as a key player in the pathogenesis of cardiovascular (atherosclerosis, coronary heart disease, stroke, hypertension), metabolic (obesity, Type II Diabetes and metabolic syndrome), neurodegenerative (ALS; Alzheimer) and immunological disorders (autoinflammatory and autoimmune diseases).

Diabetes affects around 8.3% of the U.S. population (USD 24 Million), 12% of world health expenditure, around USD 673 billion. .

In the last decade low grade, chronic, sterile inflammation has been recognized as a key player in the pathogenesis of cardiovascular (atherosclerosis, coronary heart disease, stroke, hypertension), metabolic (obesity, Type II Diabetes and metabolic syndrome), neurodegenerative (ALS; Alzheimer) and immunological disorders (autoinflammatory and autoimmune diseases).

Diabetes affects around 8.3% of the U.S. population (USD 24 Million), 12% of world health expenditure, around USD 673 billion. .

FOUNDERS

Pía Garat

Biotech Engineer
Adjunct Researcher at
Institut Pasteur de Montevideo
EOLO Pharma CEO

More Details

Carlos Batthyány

MD, PhD
Principal Investigator at
Institut Pasteur de Montevideo
EOLO Pharma CMO

More Details

Carlos Escande

PhD
Principal Investigator
Institut Pasteur de Montevideo
EOLO Pharma CSO

More Details

Virginia López

Pharmaceutical Chemist, PhD
Investigator
Institut Pasteur de Montevideo
EOLO Pharma CCO

More Details
Menu